Steve Paul, Karuna Therapeutics CEO (Third Rock)

Karuna's schiz­o­phre­nia drug pass­es a close­ly-watched PhI­II test, will head to FDA in mid-2023

An in­ves­ti­ga­tion­al pill that com­bines a for­mer Eli Lil­ly CNS com­pound with an over­ac­tive blad­der drug was bet­ter than place­bo at re­duc­ing a scale of symp­toms ex­pe­ri­enced by pa­tients with schiz­o­phre­nia in a Phase III tri­al.

Karuna Ther­a­peu­tics’ drug passed the pri­ma­ry goal in EMER­GENT-2, the Boston biotech said ear­ly Mon­day morn­ing, along­side quar­ter­ly earn­ings. The study is the first of Karuna’s four Phase III clin­i­cal tri­als to read out in schiz­o­phre­nia and will pro­vide the back­bone to the biotech’s first drug ap­proval ap­pli­ca­tion, slat­ed for mid-2023.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.